Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.
about
Evolution of stimulants to treat ADHD: transdermal methylphenidateInfluence of methylphenidate on brain development--an update of recent animal experiments.Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidateEfficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study dataLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyMechanistic insights into nicotine withdrawal.Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male ratsDopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attentionChronic administration of methylphenidate produces neurophysiological and behavioral sensitizationConverging methods in studying attention-deficit/hyperactivity disorder: what can we learn from neuroimaging and genetics?The multifaceted effects of oral administration of methylphenidate in juvenile rats: anxiety, activity, and attention.Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.Chronic methylphenidate exposure during adolescence reduces striatal synaptic responses to ethanol.Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice.Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and designDissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum.Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder.Acute oral administration of low doses of methylphenidate targets calretinin neurons in the rat septal area.Animal models to guide clinical drug development in ADHD: lost in translation?A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Osmotic, controlled-release methylphenidate for the treatment of ADHD.Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.Specificity and impact of adrenergic projections to the midbrain dopamine system.Differences in impulsivity on a delay-discounting task predict self-administration of a low unit dose of methylphenidate in rats.Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice.Differentiation of rodent behavioral phenotypes and methylphenidate action in sustained and flexible attention tasksMethylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats.Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.Sex Differences in the Physiological and Behavioral Effects of Chronic Oral Methylphenidate Treatment in RatsCatecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.A review of psychostimulant-induced neuroadaptation in developing animals.Attention-deficit/hyperactivity disorder genomics: update for clinicians.Methylphenidate as a reinforcer for rats: contingent delivery and intake escalation.Specific Components of Pediatricians' Medication-Related Care Predict Attention-Deficit/Hyperactivity Disorder Symptom Improvement.No effect of acute tryptophan depletion on verbal declarative memory in young persons with ADHD.
P2860
Q22252903-EF13FC9E-CF32-4944-8558-F3C8D15D1214Q24537917-7A51E468-18BB-47A5-80F3-D14B5CBB4325Q24658233-2E17E0DF-C32A-4BA3-8E5F-840ACBF60D9BQ24805432-EC3D51F8-B381-480A-85FB-059CA4069799Q26750486-C2848DAC-B5EE-4B4C-A5B4-70D968E4CCD0Q27687645-CE368F17-35BE-4E76-9DDD-7ACE93A22274Q28575418-D4398A83-E595-4ED4-BAF9-910FDD73E138Q30488704-C9FEA7B3-C8C6-46FB-A3A0-F118E8E0CEFAQ30544583-F4DB1789-E827-4C31-873E-5EA763690809Q33374171-318E16D7-D1CA-47A1-AF50-0F3115B75AB8Q33707978-8942089A-8B43-4AC0-A869-3805FAC621B2Q33799533-A43261F3-6B24-44C5-AE86-9C0BA5677B38Q34180506-94717528-1F71-401C-8EF4-495C05091EAEQ34217427-5DD7BE87-FE8D-449D-8BF1-55B200B01250Q34273853-AFF8579F-BFF5-48E4-96EA-380FA36DA767Q34468658-6ABC9048-1B6C-4111-A8CF-717AED64D3E2Q34543628-BEB74353-7EB2-4B59-B5CF-2D250B2A7D4EQ34719368-C8E94452-E7E3-447C-9364-BA358344C251Q35098070-E4AE06FE-4868-4E05-9C9F-CA576BEA4520Q35142888-E2DE7F62-740A-4918-8EEB-AB05C80B72CFQ35185147-C22AF874-18FA-4956-9186-6E8080678FE5Q35206689-15F493D6-0A9D-4E5A-A558-FA1B5F5F578EQ35589937-60B689CF-F7B5-4FDD-98F3-121CEF4C8C5AQ35709161-8C58596B-CD72-455C-9609-E7A9C378B198Q36446854-085021A5-7845-4FE6-9D87-E7A7C3A4B7E7Q36613947-EDA60954-250C-40DC-89D3-DD87A2B92FC4Q36618684-35352A73-6A85-498E-93BA-9D31EEB921A5Q36932568-FE2614B2-506F-42D3-926A-AE3CD51D554CQ37368242-BF10AC95-B315-45B7-99F9-3EDF90F40F2AQ37438542-BD0D806F-7439-4101-ACF0-73B05AB92090Q37451921-538574A5-6398-4117-A859-CBB61E681EB3Q37451932-292872EB-B1B0-47C2-914B-61FD1DA1E119Q37685508-65BFA838-1E5D-488E-88F4-03B5896E9924Q37723437-9C1E318D-B727-4A0A-845E-76E4A8B6D731Q37835904-B5693367-050D-467B-A9C9-29655DB9C434Q37879918-85498524-4C61-49BC-9C4B-09A2426E70C8Q38030489-D0C4D998-AE48-46F2-903D-7D930190EA6AQ38274000-01A22B74-5F59-46BC-9014-E22471CF3224Q38678798-08BFA5CB-D172-41DE-9D9B-B57FD5A1BCD8Q39465530-24396665-F3E1-424D-B547-EAD2270AFFB5
P2860
Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@en
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@nl
type
label
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@en
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@en
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@nl
P1476
Pharmacokinetic and pharmacody ...... gn of new treatments for ADHD.
@en
P2093
P356
10.1016/S0166-4328(01)00433-8
P407
P577
2002-03-01T00:00:00Z